CXCR3 and neoplasm: Finally, to determine if our hypothesis that the CXCR3 chemokine axis is a targetable driver of tumor growth, we performed in vivo experiments with both immunodeficient and immunocompetent murine models, in which appropriate SCC tumor cell lines were implanted in mice and the tumor volume and weight were compared between the antagonist of CXCR3 (AMG487)-treated and vehicle-treated groups (Figure 6A).